Galectin Therapeutics (GALT) Interest & Investment Income (2010 - 2026)
Galectin Therapeutics' quarterly Interest & Investment Income came in at $36000.0 in Q1 2026, up 2.86% year-on-year from $35000.0 in Q1 2025, and up 44.0% quarter-over-quarter from $25000.0 in Q4 2025.
Galectin Therapeutics has reported Interest & Investment Income for 17 years, with the latest figure at $36000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 2.86% year-over-year to $36000.0; the trailing twelve-month figure through Mar 2026 stood at $126000.0 (down 56.85% YoY), and the FY2025 full-year result was $126000.0, down 62.72% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $36000.0, up from $25000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $93000.0 in Q3 2024, with the low at $1000.0 in Q1 2022.
- Average Interest & Investment Income over 5 years is $45882.4, with a median of $39000.0 recorded in 2025.
- Year-over-year, Interest & Investment Income surged 4300.0% in 2023 and sank 70.24% in 2025.
- Tracing GALT's Interest & Investment Income over 5 years: stood at $30000.0 in 2022, then surged by 146.67% to $74000.0 in 2023, then grew by 13.51% to $84000.0 in 2024, then slumped by 70.24% to $25000.0 in 2025, then soared by 44.0% to $36000.0 in 2026.
- The last three Interest & Investment Income figures came in at $36000.0 (Q1 2026), $25000.0 (Q4 2025), and $39000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | 36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Sep 30, 2025 | 39,000.00 |
| Jun 30, 2025 | 26,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | 84,000.00 |
| Sep 30, 2024 | 93,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Sep 30, 2023 | 62,000.00 |
| Jun 30, 2023 | 50,000.00 |
| Mar 31, 2023 | 44,000.00 |
| Dec 31, 2022 | 30,000.00 |
| Sep 30, 2022 | 18,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 1,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Sep 30, 2020 | 5,000.00 |
| Jun 30, 2020 | 9,000.00 |
| Mar 31, 2020 | 50,000.00 |
| Dec 31, 2019 | 73,000.00 |
| Sep 30, 2019 | 101,000.00 |
| Jun 30, 2019 | 43,000.00 |
| Mar 31, 2019 | 14,000.00 |
| Dec 31, 2018 | 15,000.00 |
| Sep 30, 2018 | 15,000.00 |
| Jun 30, 2018 | 4,000.00 |
| Mar 31, 2018 | 4,000.00 |
| Dec 31, 2017 | 3,000.00 |
| Sep 30, 2017 | 6,000.00 |
| Jun 30, 2017 | 6,000.00 |
| Mar 31, 2017 | 9,000.00 |
| Dec 31, 2016 | 8,000.00 |
| Sep 30, 2016 | 11,000.00 |
| Jun 30, 2016 | 12,000.00 |
| Mar 31, 2016 | 14,000.00 |
| Dec 31, 2015 | 12,000.00 |
| Sep 30, 2015 | 12,000.00 |
| Jun 30, 2015 | 14,000.00 |
| Mar 31, 2015 | 14,000.00 |
| Dec 31, 2014 | 13,000.00 |
| Sep 30, 2014 | 12,000.00 |
| Jun 30, 2014 | 13,000.00 |
| Mar 31, 2014 | 4,000.00 |
| Dec 31, 2013 | 5,000.00 |
| Sep 30, 2013 | 3,000.00 |
| Jun 30, 2013 | 3,000.00 |
| Mar 31, 2013 | 5,000.00 |
| Dec 31, 2012 | 6,000.00 |
| Sep 30, 2012 | 7,000.00 |
| Jun 30, 2012 | 8,000.00 |
| Mar 31, 2012 | 3,000.00 |
| Dec 31, 2011 | 4,000.00 |
| Sep 30, 2011 | 5,000.00 |
| Jun 30, 2011 | 4,000.00 |
| Mar 31, 2011 | 5,000.00 |
| Dec 31, 2010 | 2,000.00 |
| Sep 30, 2010 | 3,000.00 |
| Jun 30, 2010 | 1,000.00 |